Zobrazeno 1 - 5
of 5
pro vyhledávání: '"D. M. DI MICHELE"'
Autor:
Amy L. Dunn, Adam Cuker, David Green, Cindy A. Leissinger, J. Gill, Abraham C. Schlauderaff, Bryce A. Kerlin, D. M. Di Michele, Joan Cox Gill, F. Shafer, A. Shapiro, Steven R. Lentz, Deborah L Brown, Madhvi Rajpurkar, Janna M. Journeycake, Robert R. Montgomery, Veronica H. Flood, Sandra L. Haberichter, Michael J. Paidas, Carolyn M. Bennett, Michael D. Tarantino, Roshni Kulkarni, Carol Diamond, Kenneth D. Friedman, Liesl Mathias, A. Matsunaga, Anne T. Neff, Paula M. Jacobi, Thomas C. Abshire, A. Bedros, Daniel B. Bellissimo, Margaret V. Ragni, M L Manco-Johnson, Tricia L. Slobodianuk, Pamela A. Christopherson, Barbara A. Konkle, Anjali Sharathkumar, Peter A. Kouides, A. Cohen, Eric J. Werner, John J. Strouse, Ralph A. Gruppo, Dagmar T. Stein, Jeffrey D. Hord, Raymond G. Hoffmann, Lisa N. Boggio, Leonard A. Valentino, Jeanne M. Lusher, Alice D. Ma, Donald H. Mahoney, Patricia J. Giardina
Publikováno v:
Blood. 125:2297-2304
Von Willebrand factor (VWF) contains binding sites for platelets and for vascular collagens to facilitate clot formation at sites of injury. Although previous work has shown that VWF can bind type IV collagen (collagen 4), little characterization of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a2cd799055edadce5d61fb10e1d4eb
https://doi.org/10.1182/blood-2014-11-610824
https://doi.org/10.1182/blood-2014-11-610824
Autor:
Paula H. B. Bolton-Maggs, A. Srivastava, C. A. Lee, Factor Ix Scientific, Flora Peyvandi, D. M. Di Michele, Armando Tripodi
Publikováno v:
Journal of Thrombosis and Haemostasis. 10:1938-1943
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::190ccc79cf62a889e4116c4d33ddb41c
https://doi.org/10.1111/j.1538-7836.2012.04844.x
https://doi.org/10.1111/j.1538-7836.2012.04844.x
Autor:
D. M. Di Michele
Publikováno v:
Journal of Thrombosis and Haemostasis. 9:216-225
Given the inhibitor-associated morbidity resulting from limited effective treatment options, antibody eradication is the ultimate goal of inhibitor management. The only clinically proven strategy for achieving antigen-specific tolerance to factor VII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c157ae1fba65e849ebe4f8c37268ebab
https://doi.org/10.1111/j.1538-7836.2011.04349.x
https://doi.org/10.1111/j.1538-7836.2011.04349.x
Publikováno v:
Haemophilia. 4:568-573
Because of the increased morbidity and cost of care associated with inhibitor development, immune tolerance therapy (ITT) is of crucial value in the care of haemophilia. The 24-year experience with this modality, primarily in the treatment of factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9f1ec4b62d5ddbf4d17e69bea5d7e48
https://doi.org/10.1046/j.1365-2516.1998.440568.x
https://doi.org/10.1046/j.1365-2516.1998.440568.x
Autor:
Linda M. Gerber, J. M. Lefkowitz, Constance B. Gibb, D. M. Di Michele, Quanhong Ni, A. Ganguly
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 20(2)
Haemophilia A and B are rare X-lined hemorrhagic disorders that typically affect men. Women are usually asymptomatic carriers, but may be symptomatic and, rarely, also express severe (factor VIII (FVIII) or factor IX (FIX)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5032c0d53ef2889b8574f257cd5acee
https://pubmed.ncbi.nlm.nih.gov/24533955
https://pubmed.ncbi.nlm.nih.gov/24533955